"Sean M. Healey & AMG Center for ALS Announces First Participant Dosed in Regimen G of the HEALEY ALS Platform Trial Evaluating DNL343 by Denali Therapeutics,” published by the Sean M. Healey & AMG Center for ALS
We'd like to share the exciting news that the first patient has been dosed in Regimen G of the HEALEY ALS Platform Trial, testing DNL343, an investigational product developed by Denali Therapeutics.